

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**MTA Infliximab, adalimumab and golimumab for
treating moderately to severely active ulcerative
colitis after the failure of conventional therapy
(including a review of TA140 and TA262)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

There is a need to give isoniazid as TB prophylaxis for 6 months in at risk patients, such as those from South Asia, concurrently with antiTNF therapy
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The issue raised is inherent in the use of the agents being appraised and was not expected to lead to unfair restrictions of access to treatment, and therefore not considered an equality issue relevant for the Committee discussions.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No change required to the scope

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name): ...Janet Robertson

Date: 15 November 2013